187 related articles for article (PubMed ID: 34377596)
1. The effect of concomitant use of statins, NSAIDs, low-dose aspirin, metformin and beta-blockers on outcomes in patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
Zhang Y; Chen H; Chen S; Li Z; Chen J; Li W
Oncoimmunology; 2021; 10(1):1957605. PubMed ID: 34377596
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular/anti-inflammatory drugs repurposed for treating or preventing cancer: A systematic review and meta-analysis of randomized trials.
Benjamin DJ; Haslam A; Prasad V
Cancer Med; 2024 Mar; 13(5):e7049. PubMed ID: 38491813
[TBL] [Abstract][Full Text] [Related]
3. Clinical evidence for the prognostic impact of metformin in cancer patients treated with immune checkpoint inhibitors.
Shen J; Ye X; Hou H; Wang Y
Int Immunopharmacol; 2024 Jun; 134():112243. PubMed ID: 38735258
[TBL] [Abstract][Full Text] [Related]
4. Effect of metformin on outcomes of patients treated with immune checkpoint inhibitors: a retrospective cohort study.
Chiang CH; Chen YJ; Chiang CH; Chen CY; Chang YC; Wang SS; See XY; Horng CS; Peng CY; Hsia YP; Peng CM; Chiang CH
Cancer Immunol Immunother; 2023 Jun; 72(6):1951-1956. PubMed ID: 36651967
[TBL] [Abstract][Full Text] [Related]
5. Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study.
Fiala O; Buti S; Takeshita H; Okada Y; Massari F; Palacios GA; Dionese M; Scagliarini S; Büttner T; Fornarini G; Myint ZW; Galli L; Souza VC; Pichler R; De Giorgi U; Quiroga MNG; Gilbert D; Popovic L; Grande E; Mammone G; Berardi R; Crabb SJ; Molina-Cerrillo J; Freitas M; Luz M; Iacovelli R; Calabrò F; Tural D; Atzori F; Küronya Z; Chiari R; Campos S; Caffo O; Fay AP; Kucharz J; Zucali PA; Rinck JA; Zeppellini A; Bastos DA; Aurilio G; Mota A; Trindade K; Ortega C; Sade JP; Rizzo M; Vau N; Giannatempo P; Barillas A; Monteiro FSM; Dauster B; Cattrini C; Nogueira L; de Carvalho Fernandes R; Seront E; Aceituno LG; Grillone F; Cutuli HJ; Fernandez M; Bassanelli M; Roviello G; Abahssain H; Procopio G; Milella M; Kopecky J; Martignetti A; Messina C; Caitano M; Inman E; Kanesvaran R; Herchenhorn D; Santini D; Manneh R; Bisonni R; Zakopoulou R; Mosca A; Morelli F; Maluf F; Soares A; Nunes F; Pinto A; Zgura A; Incorvaia L; Ansari J; Zabalza IO; Landmesser J; Rizzo A; Mollica V; Sorgentoni G; Battelli N; Porta C; Bellmunt J; Santoni M
Cancer Immunol Immunother; 2023 Nov; 72(11):3665-3682. PubMed ID: 37676282
[TBL] [Abstract][Full Text] [Related]
6. Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications.
Spakowicz D; Hoyd R; Muniak M; Husain M; Bassett JS; Wang L; Tinoco G; Patel SH; Burkart J; Miah A; Li M; Johns A; Grogan M; Carbone DP; Verschraegen CF; Kendra KL; Otterson GA; Li L; Presley CJ; Owen DH
BMC Cancer; 2020 May; 20(1):383. PubMed ID: 32375706
[TBL] [Abstract][Full Text] [Related]
7. The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer.
Amin S; Boffetta P; Lucas AL
Gut Liver; 2016 Sep; 10(5):665-71. PubMed ID: 27563018
[TBL] [Abstract][Full Text] [Related]
8. Regular Use of Aspirin and Statins Reduces the Risk of Cancer in Individuals with Systemic Inflammatory Diseases.
Lin JR; Han DD; Wei W; Zeng Q; Rong ZX; Bai X; Zhang YP; Wang J; Cai XT; Rao XG; Ma SC; Dong ZY
Cancer Res; 2024 Jun; 84(11):1889-1897. PubMed ID: 38536116
[TBL] [Abstract][Full Text] [Related]
9. Effect of Concomitant Medications on Treatment Response and Survival in De Novo Metastatic Prostate Cancer: Secondary Analysis of the LATITUDE Study.
Roy S; Saad F; Wallis CJD; Sun Y; Spratt DE; Akilla R; Kishan AU; Malone S; Morgan SC
Eur J Cancer; 2024 Mar; 199():113348. PubMed ID: 38262848
[TBL] [Abstract][Full Text] [Related]
10. Obesity and cancer: mechanistic insights from transdisciplinary studies.
Allott EH; Hursting SD
Endocr Relat Cancer; 2015 Dec; 22(6):R365-86. PubMed ID: 26373570
[TBL] [Abstract][Full Text] [Related]
11. Influence of Microbiome and Antibiotics on the Efficacy of Immune Checkpoint Inhibitors.
Patel P; Poudel A; Kafle S; Thapa Magar M; Cancarevic I
Cureus; 2021 Aug; 13(8):e16829. PubMed ID: 34522484
[TBL] [Abstract][Full Text] [Related]
12. Geriatric predictors of response and adverse events in older patients with cancer treated with immune checkpoint inhibitors: A systematic review.
Özkan A; van den Bos F; Mooijaart SP; Slingerland M; Kapiteijn E; de Miranda NFCC; Portielje JEA; de Glas NA
Crit Rev Oncol Hematol; 2024 Feb; 194():104259. PubMed ID: 38199430
[TBL] [Abstract][Full Text] [Related]
13. Association of opioid use with survival in patients with cancer treated with immune checkpoint inhibitors: it is time for evidence-based behaviors.
Giusti R; Porzio G; Maltoni M; Filetti M; Cuomo A; Bandieri E; Trapani D; Bruera E
Oncologist; 2024 Apr; ():. PubMed ID: 38688456
[TBL] [Abstract][Full Text] [Related]
14. Metformin and Statins and their role in reducing Hepatocellular Carcinoma Risk: Randomized trials are needed.
Kwo PY
Clin Mol Hepatol; 2024 Jun; ():. PubMed ID: 38858181
[No Abstract] [Full Text] [Related]
15. Comedications with Immune Checkpoint Inhibitors: Involvement of the Microbiota, Impact on Efficacy and Practical Implications.
Colard-Thomas J; Thomas QD; Viala M
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190203
[TBL] [Abstract][Full Text] [Related]
16. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis.
Zhou X; Yao Z; Bai H; Duan J; Wang Z; Wang X; Zhang X; Xu J; Fei K; Zhang Z; Tan F; Xue Q; Gao S; Gao Y; Wang J; He J
Lancet Oncol; 2021 Sep; 22(9):1265-1274. PubMed ID: 34391508
[TBL] [Abstract][Full Text] [Related]
17. Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events.
Kostine M; Mauric E; Tison A; Barnetche T; Barre A; Nikolski M; Rouxel L; Dutriaux C; Dousset L; Prey S; Beylot-Barry M; Seneschal J; Veillon R; Vergnenegre C; Daste A; Domblides C; Sionneau B; Gross-Goupil M; Ravaud A; Forcade E; Schaeverbeke T;
Eur J Cancer; 2021 Nov; 157():474-484. PubMed ID: 34649118
[TBL] [Abstract][Full Text] [Related]
18. Hepatotoxicity Induced by Fluvastatin: A Reversible Acute Cholestatic Liver Injury.
Alanazi NS; Alenazi TS; Alenzi KA
Am J Case Rep; 2021 Aug; 22():e931418. PubMed ID: 34383728
[TBL] [Abstract][Full Text] [Related]
19. Thyroid dysfunction and survival in cancer patients treated with immune checkpoint inhibitors: analyses from a large single tertiary cancer center database.
Percik R; Liel Y; Urban D; Bar J; Ben-Ami E; Abu Tailakh M
Acta Oncol; 2021 Nov; 60(11):1466-1471. PubMed ID: 34379562
[TBL] [Abstract][Full Text] [Related]
20. Concomitant Statins and the Survival of Patients with Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Meta-Analysis.
Zhang L; Wang H; Tian J; Sui L; Chen X
Int J Clin Pract; 2022; 2022():3429462. PubMed ID: 35855055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
